Octapharma Plasma Credit Rating & NNN Cap Rate Analysis

Octapharma Plasma Business Overview & NNN Investment Profile

Octapharma Plasma is the U.S. plasma collection subsidiary of Octapharma AG, a Swiss-based global biopharmaceutical company and one of the world’s largest manufacturers of human protein products derived from blood plasma. Octapharma AG generates approximately €3.4 billion in annual revenue and operates across 118 countries, with a workforce exceeding 12,000 employees. The company is privately held by the Staber family and has been in operation since 1983, giving it four decades of experience in plasma-derived therapeutics. In the United States, Octapharma Plasma operates approximately 190 collection centers, making it one of the top three plasma collectors in the country alongside CSL Plasma and BioLife Plasma Services.

For NNN investors, Octapharma Plasma centers represent a distinctive healthcare property type: purpose-built or extensively renovated facilities designed for high-volume plasma donation. These centers are typically 10,000 to 20,000 square feet, located in suburban retail corridors or strip centers, and configured with donor beds, medical screening areas, laboratory processing equipment, and cold storage. The demand for source plasma is structural and growing, driven by an expanding global market for immunoglobulins, clotting factors, and albumin used to treat immune deficiencies, bleeding disorders, and other serious medical conditions. The United States supplies approximately 70% of the world’s source plasma, making domestic collection centers a critical link in the global biopharmaceutical supply chain.

Why Octapharma Plasma Matters for NNN Investors

Plasma collection is one of the most essential and fastest-growing segments of the healthcare real estate market. Global demand for plasma-derived therapies has grown at approximately 8% to 10% annually for the past decade, driven by increasing diagnosis of primary immune deficiencies, an aging population requiring more immunoglobulin therapy, and expanding access to treatment in emerging markets. The supply of source plasma is the binding constraint on the entire industry, which means collection centers in the United States are critical infrastructure that cannot be easily relocated, downsized, or shut down without significant regulatory and supply chain consequences.

Octapharma Plasma leases are typically structured as NNN with 10 to 15 year initial terms, annual escalations of 2% to 3%, and corporate guarantees from the U.S. operating entity. The specialized nature of plasma centers (FDA-regulated, requiring specific HVAC, plumbing, and electrical configurations) means that re-tenanting for non-plasma use requires meaningful investment. However, the strong demand from competing plasma collectors (CSL, BioLife/Takeda, Grifols) means that a vacated Octapharma center in a viable market would attract interest from other plasma operators, providing sector-specific re-tenanting potential.

Cap Rate Analysis & Pricing for Octapharma Plasma NNN Properties

Octapharma Plasma NNN properties trade in the 6.25% to 7.75% cap rate range as of Q1 2026. The absence of a public credit rating prevents direct comparison with rated peers, but the strong qualitative credit profile positions Octapharma tighter than the publicly rated Grifols (BB/Ba3 Negative, 7.00%+ cap rates) and comparable to the stronger end of the CSL Plasma (A‑/A3) and BioLife Plasma (BBB‑/Baa3) cap rate ranges. Pricing typically ranges from $2.5 million to $10 million for these larger-format facilities.